Ranbaxy’s “Persistent” Data Integrity Problems, Systemic GMP Violations Drove Consent Decree
Executive Summary
The generic drug manufacturer’s settlement with FDA resulted from a series of violations identified through agency inspections of five company sites in India and the U.S. dating back to 2006, according to the government’s complaint for permanent injunction.